We provide evidence that S6 kinase 1 (S6K1) Aly/REF-like target (SKAR) is engaged in IFN-α signaling and plays a key role in the generation of IFN responses. Our data demonstrate that IFN-α induces phosphorylation of SKAR, which is mediated by either the p90 ribosomal protein S6 kinase (RSK) or p70 S6 kinase (S6K1), in a cell type-specific manner. This type I IFN-inducible phosphorylation of SKAR results in enhanced interaction with the eukaryotic initiation factor (eIF)4G and recruitment of activated RSK1 to 5′ cap mRNA. Our studies also establish that SKAR is present in cap-binding CBP80 immune complexes and that this interaction is mediated by eIF4G. We demonstrate that inducible protein expression of key IFN-α-regulated protein products such as ISG15 and p21 WAF1/CIP1 requires SKAR activity. Importantly, our studies define a requirement for SKAR in the generation of IFN-α-dependent inhibitory effects on malignant hematopoietic progenitors from patients with chronic myeloid leukemia or myeloproliferative neoplasms. Taken altogether, these findings establish critical and essential roles for SKAR in the regulation of mRNA translation of IFN-sensitive genes and induction of IFN-α biological responses.
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S tudies over several decades have firmly established that interferons (IFNs) exhibit important antiviral, immunomodulatory, and antineoplastic properties (1) (2) (3) (4) (5) (6) . Indeed, IFNs have shown important therapeutic properties and have been used extensively for the treatment of many human diseases, including infections, neurological disorders, and malignancies (6) (7) (8) (9) (10) . Dysregulation of IFN gene expression and abnormally high IFN production contribute to the pathophysiology of certain diseases, and efforts are under way to limit IFN production or minimize their target effects to ameliorate disease (5, (11) (12) (13) .
Type I IFNs generate biological responses by binding to specific cell-surface receptors and activating Jak-STAT signaling to mediate transcription of IFN-stimulated genes (ISGs) (14) (15) (16) . In addition to Jak-Stat signaling, several other signaling cascades are activated following receptor activation and are essential for optimal transcriptional regulation and mRNA translation of ISGs (17) . Among these are MAP kinase (MAPK) pathways and their effectors (18) . In particular, the p38 MAPK pathway is of critical importance for type I IFN-dependent gene transcription and acts in an independent but complementary manner to JakStat signaling (19) . IFN-inducible MAPK-dependent signaling is critical for the control of IFN-induced mRNA translation and protein expression for key ISGs and, further downstream, Mnk kinases are essential for IFN-inducible protein expression and generation of IFN responses (20, 21) .
The mTOR pathway plays a central role in the control of diverse cellular functions (22) and, in recent years, its activation and functional relevance in IFN signaling have been shown (23) (24) (25) (26) . Notably, mTOR-induced signals are relevant for the mRNA translation of genes whose transcription is regulated by Jak-Stat pathways, providing a link between Jak-Stat pathways and the signals needed for the ultimate expression of protein products of Stat-dependent genes (25, 26) . Despite these advances in understanding the role of the mTOR pathway in IFN signaling, the precise contribution and unique roles of distinct mTOR effectors in cap-dependent mRNA translation of ISGs remain to be precisely defined.
In the present study, we provide evidence that S6 kinase 1 (S6K1) Aly/REF-like target (SKAR) is an IFN-α-activated effector of either MAPK pathways downstream of p90 ribosomal protein S6 kinase (RSK1) or mTORC1 complexes downstream of S6K1. Our studies demonstrate that IFN-α-inducible phosphorylation of SKAR results in enhanced interactions of the protein with the eukaryotic initiation factor (eIF)4G and the formation of a unique IFN-inducible RSK1-SKAR-eIF4G complex. Knockdown of SKAR results in defective mRNA translation of key ISGs and reverses generation of the antileukemic/antineoplastic effects of IFN-α on malignant hematopoietic progenitors from patients with chronic myeloid leukemia (CML) or polycythemia vera, establishing a key role for this protein in the generation of IFN-α responses.
Results
Previous studies in other systems have identified SKAR as an mTOR/S6K1 effector recruiting S6K1 to cap-binding complex Significance Type I interferons (IFNs) are cytokines with important biological effects, including antileukemic and antineoplastic properties. The biological responses of type I IFNs occur via uptranscriptional activation of specific genes, called interferonstimulated genes (ISGs), ultimately resulting in generation of protein products that mediate their biological effects. In the present study, we provide evidence that the protein S6 kinase 1 Aly/REF-like target (SKAR) plays a critical role in IFN-dependent mRNA translation of ISGs and recruits activated p90 ribosomal protein S6 kinase to the translational machinery. Our data provide evidence for critical and essential roles for SKAR in the generation of type I IFN-dependent antileukemic and antineoplastic responses, underscoring the importance of SKAR functions in IFN signaling.
(CBC) mRNA and enhancing translation efficiency (27, 28) . As we have previously shown that the IFN-activated mTOR pathway has a critical role in mRNA translation of ISGs and generation of IFN responses (23) (24) (25) (26) , we sought to determine whether SKAR is an IFN-engaged mTOR effector and plays a role in type I IFN signaling. At the outset, we sought to determine whether SKAR is engaged in IFN signaling in malignant hematopoietic cells. Based on evidence that the consensus amino acid motif RXRXX*S/*T is present in SKAR (27), we examined whether there is IFN-inducible phosphorylation of SKAR on this motif. KT1 or U937 cells were treated for different times with IFN-α, and total cell lysates were immunoprecipitated with an anti-SKAR antibody. Phosphorylated SKAR was then identified by immunoblotting using the anti-phospho-RXRXX*S/*T antibody. IFN-α treatment resulted in phosphorylation of SKAR both in KT1 (Fig. 1A ) and U937 cells (Fig. S1 ), suggesting that this protein is engaged in IFN-α signaling.
Previous studies have established that SKAR can be found in CBP80-bound mRNA protein complexes (28) . To determine whether IFN treatment results in formation of CBP80-SKAR complexes, coimmunoprecipitation studies were performed. Serum-starved KT1 cells were treated with IFN-α, and then cell lysates were either left untreated, treated with RNase A, or immunoprecipitated with an anti-CBP80 antibody. IFN treatment increased the levels of SKAR protein present in CBP80 complexes, independent of treatment with RNase A. As expected (29) (30) (31) , eIF4G was detected in association with CBP80 (Fig. 1B) .
In subsequent studies, we sought to identify the IFN-dependent serine kinase that regulates phosphorylation of SKAR. Given our earlier evidence for differential, cell type-dependent phosphorylation of eIF4B and programmed cell death 4 (PDCD4) protein by either S6K1 or RSK1 (32, 33), we initially examined whether pharmacological inhibition of mTOR or RSK activity can abrogate SKAR phosphorylation. Serum-starved KT1 hematopoietic cells were preincubated with the catalytic mTOR inhibitor OSI-027 or the RSK1 inhibitor BI-D1870 and then treated with IFN-α before immunoprecipitation of cell lysates with the anti-SKAR antibody. IFN-α-induced phosphorylation of SKAR was detectable in cells treated with the mTOR inhibitor, but it was blocked in cells treated with the RSK inhibitor (Fig. 1C) . Moreover, the extent of phosphorylation of SKAR after IFN-α treatment correlated with the amount of eIF4G detected in SKAR immunoprecipitates, suggesting that IFN treatment induces an association of the phosphorylated form of SKAR with eIF4G (Fig. 1C) . Consistent with this, IFN-α-induced SKAR-eIF4G complex formation was not detected in cells pretreated with the RSK inhibitor (Fig. 1C) .
To further define the involvement of RSK1 in SKAR phosphorylation, experiments were carried out in which RSK1 was knocked down in KT1 cells. As shown in Fig. 1D , siRNAmediated inhibition of RSK1 expression partially blocked SKAR phosphorylation, indicating that in these cells RSK1 is the dominant kinase controlling IFN-dependent SKAR phosphorylation (Fig. 1D) . Consistent with this, when immune complex kinase assays were performed on anti-RSK1 immunoprecipitates from IFN-treated KT1 cells using GST-SKAR as a substrate, we found strong SKAR phosphorylation by the IFN-α-activated RSK1 (Fig. 1E) . Similarly, RSK inhibition blocked IFN-induced phosphorylation of exogenously overexpressed SKAR protein in KT1 cells (Fig. S2 ), further establishing a role for RSK1 in IFNinducible SKAR phosphorylation on the RXRXX*S/*T motif. Altogether, these studies definitively establish that SKAR is a substrate for RSK1 in cells of hematopoietic origin.
To determine whether S6K1 may also have a role in IFN-α-inducible SKAR phosphorylation, we conducted a series of experiments in immortalized mouse embryonic fibroblasts (MEFs) with targeted disruption of either the S6k1 or S6k2 gene or both. Serum-starved S6k1/2
, and double S6k1/S6k2 knockout MEFs were treated with mouse IFN-α, total lysates were immunoprecipitated with a SKAR antibody, and phosphorylated SKAR was examined by anti-phospho-RXRXX*S/*T Equal amounts of total cell lysates were subjected to IP using anti-SKAR antibodies conjugated to biotin and pulled down by streptavidin agarose. The immunoprecipitates were resolved by SDS/PAGE and immunoblotted with either the anti-phospho-RXRXX*S/*T motif antibody or an anti-SKAR antibody. (E) Serum-starved KT1 cells were treated with IFN-α for the indicated times. The cells were lysed and equal amounts of protein were immunoprecipitated with an anti-RSK1 antibody or control RIgG. In vitro kinase assays were then carried out in the immunoprecipitates, using GST-SKAR as an exogenous substrate. Samples were resolved by SDS/ PAGE, and the phosphorylated form of GST-SKAR is shown (Upper). Anti-RSK1 immunoblotting of total cell lysates from the same experiment with the in vitro kinase assay is also shown (Lower).
motif immunoblotting. IFN-α-inducible SKAR phosphorylation was defective in S6k1 knockout cells and double S6k1/S6k2 knockout cells but not in single S6k2 knockout cells, demonstrating a cell typespecific, selective requirement for S6k1 but not S6k2 in the process (Fig. S3 ). Earlier studies in other systems have identified SKAR as an S6K1-interacting protein recruiting S6K1 to CBC mRNA (28) . SKAR and eIF4G are found in CBP80 immune complexes, but the specific protein that interacts directly with SKAR has not been identified (28) . The nuclear CBC involves a CBP20 and CBP80 heterodimer that interacts with the 5′ cap structure of mRNA (34) (35) (36) and functions analogous to the cap-bound eIF4E as a translation initiation factor (37) . Using 7-methyl-GTP-Sepharose as a mimic of the 5′ cap structure, we undertook studies to identify which factors are important for the recruitment of SKAR to the complex. As shown in Fig. 2A , IFN-α treatment resulted in enhanced binding of eIF4G and eIF4A to the 5′ cap structure, and knockdown of eIF4G ( Fig. 2A) decreased not only the amount of eIF4A but also of SKAR ( Fig.  2A) . In lysates from cells transfected with eIF4G-specific siRNA, we found less SKAR in CBP80 complexes compared with lysates from cells transfected with control siRNA (Fig. 2B) , suggesting that eIF4G is the necessary protein for binding of SKAR to the complex. To confirm this, we used lysates from cells transfected with control siRNA or siRNA specifically targeting CBP80. As expected, CBP80 knockdown resulted in decreased levels in the amount of CBP20 in 5′ cap complexes (Fig. 2C) . Notably, siRNAmediated CBP80 knockdown did not affect the amount of SKAR found in the 5′ cap complexes, further supporting that eIF4G is the mediator of SKAR binding to the complex (Fig. 2C) .
Because our studies suggested that RSK1 is required for SKAR phosphorylation in cells of hematopoietic origin, we next examined whether RSK1 associates with SKAR during IFN-α treatment of cells. As shown in Fig. 3A , the IFN-inducible phosphorylated form of RSK1 was detected in SKAR immunoprecipitates (Fig. 3A) , in support of a physical interaction between SKAR and RSK1. To confirm this finding, protein-binding assays were used. Equal amounts of phosphorylated/activated His-tagged-RSK1 (His-RSK1) and the dephosphorylated form of His-RSK1 (as a result of PP2A treatment) (Fig. S4) were mixed with GST-SKAR (Fig. 3B) . Immunoblot analysis of eluted fractions from a His60 Ni Superflow resin column demonstrated the presence of GST-SKAR together with activated His-RSK1, whereas the dephosphorylated form of His-RSK1 did not bind to GST-SKAR (Fig. 3C) , providing further evidence that only the activated form of RSK1 binds to SKAR.
To examine the role of SKAR in eIF4G binding to the 5′ cap complex, we conducted a series of experiments using lysates from cells transfected with control siRNA or siRNA specifically targeting SKAR. As anticipated (Fig. 3D) , we found that IFN treatment resulted in enhanced recruitment/binding of eIF4G to GTP conjugated to beads and, after extensive washing, bound proteins were eluted and resolved by SDS/PAGE and immunoblotted with antibodies against eIF4G, SKAR, p-Ser221-RSK1, and CBP80. (E) The same lysates used for the experiment in D were resolved by SDS/PAGE and immunoblotted with the indicated antibodies. The immunoblot for SKAR and phospho-PDCD4 was from the same gel, and the other immunoblots were from a separate gel run in parallel from the same lysates. the 5′ cap complex, which was clearly detectable in lysates from cells in which SKAR was knocked down, but knockdown of SKAR dramatically decreased the levels of phosphorylated RSK1 compared with lysates from cells transfected with control siRNA (Fig. 3D) .
We have previously shown that eIF4B and PDCD4 are phosphorylated by RSK1 during IFN-α treatment of hematopoietic cells and that their phosphorylation is important for regulation of mRNA translation of ISGs (32, 33) . Accordingly, we hypothesized that the SKAR interaction with eIF4G may result in positioning phospho-RSK1 in close proximity to the translational machinery. To test this, we examined phosphorylation of eIF4B and PDCD4 in lysates from cells transfected with either control siRNA or siRNA targeting SKAR and treated with IFN-α. Phosphorylation of eIF4B and PDCD4 was diminished in lysates from cells transfected with siRNA targeting SKAR and IFN-treated (Fig. 3E and Fig. S5 A and B) . Moreover, PDCD4 levels were higher in SKAR siRNA-transfected cells compared with control siRNA-transfected cells, consistent with the observation that nonphosphorylated PDCD4 is resistant to proteosomal degradation (33) . On the other hand, IFNinducible phosphorylation of RSK1 and the S6 ribosomal protein (rpS6) was not affected by SKAR knockdown.
In subsequent studies, we examined the functional relevance of SKAR in mRNA translation of ISGs and the generation of IFN responses. In experiments to directly establish whether SKAR engagement in IFN signaling is important for ISG expression, we found that SKAR knockdown results in defective IFN-dependent induction of ISG15 and p21 WAF1/CIP1 proteins (Fig. 4A) . The inhibitory effects on ISG15 and p21 WAF1/CIP1 protein expression in cells in which SKAR was knocked down were not the result of suppression of IFN-α-dependent transcription of these genes (Fig. 4 B and C) , suggesting effects on mRNA translation. In parallel studies in which SKAR was overexpressed in KT1 cells, IFN-α-dependent ISG protein expression, including ISG15 and p21 WAF1/CIP1 , was increased (Fig.  4D) . To determine whether the regulatory effects of SKAR on ISG protein expression reflect effects on mRNA translation of key ISGs, we examined the effects of siRNA-mediated knockdown of SKAR on ISG15 and p21 WAF1/CIP1 mRNA expression in polysomal fractions from KT1 cells (Fig. 4 E-G) . We found a significant decrease of IFN-α-induced ISG15 and p21 WAF1/CIP1 polysomal mRNA expression in cells in which SKAR was knocked down (Fig. 4 F and G) , establishing an essential role for SKAR in mRNA translation of these key ISGs.
In subsequent studies, we examined the potential involvement of SKAR in the generation of the antileukemic effects of IFN-α. We assessed the effects of SKAR knockdown on the generation of the inhibitory effects of IFN-α on leukemic progenitor colony formation. IFN treatment suppressed CFU-blast (CFU-L) colony formation of KT1 cells transfected with control siRNA, but this inhibition was ablated by SKAR knockdown (Fig. 5A) . Similarly, siRNA knockdown of SKAR in primary leukemic CFU-GM progenitors from CML patients (Fig. 5B) , or in primary malignant early erythroid progenitors (BFU-E) from patients with polycythemia vera (Fig. 5C ), reversed the inhibitory effects of IFN-α on colony formation, strongly suggesting that SKAR plays an important role in the generation of the antileukemic and antineoplastic effects of IFN-α.
To determine whether SKAR has a role in the generation of IFN-α responses in nonhematopoietic malignant cells, we assessed the effects of SKAR knockdown on the suppressive effects of IFN-α on anchorage-independent growth of malignant colon adenocarcinoma HT29 cells. IFN-α treatment resulted in inhibition of anchorage-independent growth of HT29 cells (Fig. S6  A and B) , but this inhibition was reversed by SKAR knockdown (Fig. S6 A and B) . In other experiments, we examined the effects of overexpression of SKAR and the ability of IFN-α to suppress anchorage-independent HT29 cell growth. Ectopic expression of SKARα did not affect baseline anchorage-independent growth but significantly enhanced the inhibitory effects of IFN-α (Fig.  S6 C and D) , further establishing an important role for SKAR in the generation of the antineoplastic effects of IFN-α. (C) genes was assessed by quantitative real-time RT-PCR using Gapdh for normalization. Data are expressed as fold increase in IFN-α-treated samples over untreated samples and represent means ± SE of four independent experiments for B and means ± SE of five experiments for C. (D) KT1 cells were transfected with pEGFP-N1 or pEGFP-N1/SKARα and, after serum starvation, were treated with IFN-α, as indicated. Equal amounts of total cell lysates were resolved by SDS/PAGE and immunoblotted with anti-GFP, antip21 WAF1/CIP1 , anti-ISG15, or anti-GAPDH antibodies. (E) KT1 cells were transfected with either control siRNA or siRNA specifically targeting SKAR and, after serum starvation, either left untreated (UT) or treated with IFN-α for 24 h. Cell lysates were resolved on a 10-50% sucrose gradient, and the absorbance at 254 nm of serial fractions was recorded. The optical density at 254 nm is shown as a function of gradient depth for each experiment. Fractions indicated as polysomes were collected and used for mRNA isolation. (F and G) Quantitative real-time RT-PCR was used to detect Isg15 (F) and p21 WAF1/CIP1 (G) mRNA expression in polysomal fractions using Gapdh for normalization. Data are expressed as fold increase in IFN-α-treated samples over untreated samples and represent means ± SD of three independent experiments, including the one shown in E. For F, two-tailed paired t test analysis showed P = 0.038 for the combination of control siRNA and IFN-α versus the combination of SKAR siRNA and IFN-α. For G, two-tailed paired t test analysis showed significance, P = 0.018, for the combination of control siRNA and IFN-α versus the combination of SKAR siRNA and IFN-α.
Discussion
In recent years, there has been accumulating evidence that the mTOR and MEK/ERK pathways are essential elements of signaling following activation of IFN receptors and play key roles in controlling initiation of mRNA translation for several ISGs and expression of their protein products, ultimately controlling the generation of specific IFN-functional responses (20, 23-26, 32, 33, 38) . Signaling elements of the two pathways have been found in close proximity to the translational machinery, facilitating a sequence of signaling events that results in activation of multiple signaling substrates. mTORC1 interacts with eIF3 and phosphorylates S6K at Thr389, and this leads to release of S6K from the eIF3 complex (39) . Other studies have shown that Mnk interacts with eIF4G and that this brings Mnk in close proximity to its substrate, eIF4E (40) . Nonphosphorylated RSK1 can interact with eIF4E-binding protein 1 (4E-BP1) in HT29 cells (38) , and S6K and RSK1 phosphorylate the same set of proteins involved in translation regulation, in a cell type-differential manner, suggesting some overlapping functions and the existence of cellular elements that define specificity. In earlier studies, we provided evidence that RSK activity is required for phosphorylation of several elements in pathways involved in mRNA translation (32, 33, 38) . However, the precise molecular mechanisms by which IFN-activated RSK interacts with various effector substrates are not well-understood.
Studies in other systems suggest that many of the protein elements involved in steady-state translation participate in the first round of mRNA translation (41) . As mentioned, the nuclear CBC involves a CBP20 and CBP80 heterodimer that interacts with the 5′ cap structure of mRNA (34) (35) (36) and functions analogously to the cap-bound eIF4E as a translation initiation factor (37) . The CBC, as well as eIF4E, interacts directly with eIF4G, the protein that binds eIF3, and subsequently recruits the 40S ribosomal subunit-containing preinitiation complex to the mRNA (29, 31) . CBP80 also interacts with the components of the exon junction complex (EJC) (42, 43) , a group of proteins localized 20-24 nt upstream of exon-exon junctions. Before the steady-state translation initiation complex is formed, mammalian mRNA undergoes quality control (44) . Studies show that if translation termination is premature, then the mRNA is subject to nonsensemediated decay and that this process requires the splicingdependent deposition of EJC proteins (43, 44) , necessary for the splicing-dependent increase in gene expression by a mechanism involving association of spliced mRNA with polysomes (44) (45) (46) . SKAR, a downstream target of S6K, is a component of the EJC, linking mTOR/S6K signaling to the first round of translation of newly processed mRNA (28, 46) . SKAR enhances translation efficiency and recruits activated S6K1 to the translational machinery, but the biological significance of its phosphorylation is not well-defined (28) .
In the present study, we examined whether IFN-α recruits SKAR to the translational machinery, and the functional relevance of this event in IFN signaling. Our data demonstrate that IFN-α treatment induces phosphorylation of SKAR, which is cell type-dependent, occurring in an S6K1-dependent manner in MEFs and in an RSK1-dependent manner in cell lines of hematopoietic origin. To our knowledge, beyond providing the first evidence for an involvement of SKAR in IFN-α signaling, our findings for the first time demonstrate a role for RSK1 in SKAR phosphorylation and show that this phosphorylation increases the affinity of SKAR for eIF4G. Importantly, the interaction of SKAR with eIF4G appears to bring activated RSK1 in contact with the translational machinery. These findings raise the possibility of a unique function for SKAR, playing an essential role in facilitating the interaction of activated RSK1 with the translational initiation complex and allowing phosphorylation of proteins involved in mRNA translation of ISGs. This is important, because in previous studies, we demonstrated that RSK can act as a type I IFN-dependent kinase for eIF4B and PDCD4 in hematopoietic cells (32, 33) and as a type III IFN-dependent kinase for 4E-BP1 in HT29 cells (38) . Our data now establish that phosphorylation of eIF4B or PDCD4 is diminished in SKAR knockdown cells, suggesting a potentially important role for SKAR in regulating localization of RSK1 and indirectly controlling its kinase activity in the cap translation complex. Notably, siRNA-mediated knockdown of SKAR resulted in decreased ISG15 and p21 WAF1/CIP1 mRNA translation, further supporting this concept. Importantly, our studies provide evidence for a requirement for SKAR activity in the generation of antineoplastic responses by type I IFNs in different systems, including effects on anchorage-independent growth of malignant adenocarcinoma cells and generation of inhibitory effects on primitive leukemic precursors from CML patients and malignant erythroid precursors from myeloproliferative neoplasm patients. Altogether, our findings underscore the importance of SKAR in the generation of IFN-α responses and further establish the relevance of mRNA translation pathways in the generation of the antineoplastic effects of IFNs. They also support a model in which SKAR plays an important regulatory role in the selective expression of ISG products to promote induction of the antitumor effects of IFNs.
Materials and Methods
Cells and Reagents. KT1, U937, and HT29 cells were grown in RPMI medium 1640 with 10% FBS and antibiotics. OSI-027 (ChemieTek) and BI-D1870 
